Trial ‘shows switching to Juul reduces toxins like stopping smoking’

A clinical trial funded by Juul purports to show that switching to the company’s e-cigarette products reduces the risk of toxins in a similar manner to stopping smoking altogether

Unlock access

Want the full analysis? Let's talk

We share insights with professionals we’re in contact with. Let us know a bit about your interest.

"*" indicates required fields

Corporate Email*

Company Name*

Name*

Department*

Industry*

Job title*

Company size*

Are you a decision-maker?*

Work Telephone*

How did you hear about us?*

How are you related to the industry?*

Tell us what you're interested in*

This field is for validation purposes and should be left unchanged.

I'm already a subscriber

Daniel Mollenkamp

The global e-cigarette market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

ECigIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

LATEST ALERTS

Trial ‘shows switching to Juul reduces toxins like stopping smoking’

Daniel Mollenkamp

Our Key Benefits

Sign up to our newsletter

LATEST ALERTS

Want the full analysis? Let's talk

Daniel Mollenkamp

Our Key Benefits

Want the full analysis? Let's talk

Sign up to our newsletter

Curious to see ECigIntelligence in action?